Filing Details
ALNYLAM PHARMACEUTICALS, INC. (NASDAQ:ALNY) filed a Form 8-K with the Securities and Exchange Commission on July 30, 2026, disclosing a material event.
8k filedNASDAQ:ALNY
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Reports Material Event to SEC
Filing Details ALNYLAM PHARMACEUTICALS, INC. (NASDAQ:ALNY) filed a Form 8-K with the Securities and Exchange Commission on July 30, 2026, disclosing a material event. Market…
Market Context
ALNYLAM PHARMACEUTICALS, INC.'s stock currently trades at $205.48 with a market capitalization of $44.2B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ALNYLAM PHARMACEUTICALS, INC.'s stock.
All SEC filings for ALNYLAM PHARMACEUTICALS, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ALNY Stock Page
Frequently Asked Questions
Where can I read ALNY's SEC filings?
Browse all filings on our ALNY SEC filings page.
What types of SEC filings does ALNYLAM PHARMACEUTICALS, INC. file?
Public companies like ALNYLAM PHARMACEUTICALS, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.